How Doctors Diagnose Heart Disease
Understanding how doctors diagnose heart disease is valuable for every patient who has been referred to a cardiologist, told their cardiac tests need follow-up, or who is trying to make sense of a complex cardiac evaluation. The diagnostic process is not arbitrary — it follows a logical, evidence-based pathway in which each test is selected based on the clinical question raised by the prior evaluation, the pre-test probability of disease in that specific patient, and the test’s performance characteristics for answering that question.
Heart disease is not a single condition — it encompasses coronary artery disease (CAD), heart failure, arrhythmias, valvular heart disease, cardiomyopathies, pericardial disease, and vascular disease — and the diagnostic pathway differs significantly depending on which condition is suspected. This guide maps out how cardiologists build a diagnosis from initial presentation through the full diagnostic evaluation, what each test contributes, and how the pieces fit together into a clinical diagnosis that drives treatment decisions.
Step 1 — History and Physical Examination: The Foundation of Cardiac Diagnosis
Every cardiac diagnostic evaluation begins with a systematic history and physical examination. Despite the sophistication of modern cardiac imaging, the history and physical exam remain indispensable because they establish the pre-test probability of disease — the single most important determinant of how to interpret subsequent test results and which tests to order:
Symptom characterization: Chest pain is the most common reason for cardiac referral, and careful characterization of chest pain type is the first step in establishing pre-test CAD probability. Typical angina has three features: substernal pressure or heaviness (rather than sharp, pleuritic, or positional pain); triggered by exertion or emotional stress; and relieved by rest or nitroglycerin within minutes. A patient with all three features has a high pre-test probability of CAD regardless of age or sex — additional testing is aimed at quantifying severity and planning treatment. Atypical chest pain has only two of the three features. Non-cardiac chest pain has fewer than two features and is likely musculoskeletal, esophageal, or pulmonary in origin. Dyspnea (shortness of breath) can indicate heart failure (orthopnea — inability to lie flat without breathlessness suggests elevated pulmonary venous pressure from LV dysfunction or mitral stenosis), pulmonary disease, anemia, or deconditioning — the history distinguishes these by onset, positional variation, exertional threshold, and associated symptoms.
Risk factor assessment: Established cardiovascular risk factors — hypertension, diabetes, dyslipidemia, smoking, family history of premature CAD (first-degree relative with MI before age 55 in men or 65 in women), obesity, and chronic kidney disease — substantially modify the pre-test probability of CAD. A 65-year-old diabetic man with 40 pack-years of smoking and typical angina has a very high pre-test CAD probability — diagnostic testing is aimed at confirming anatomy and planning revascularization, not at ruling disease in or out. A 35-year-old woman with no risk factors and non-cardiac chest pain has a low pre-test probability — a normal stress test effectively excludes hemodynamically significant CAD.
Physical examination findings: The cardiac exam provides diagnostic information that complements the history and cannot be obtained from any test in isolation. Elevated jugular venous pressure indicates right heart congestion. An S3 gallop (low-pitched third heart sound in early diastole) indicates LV dilatation and elevated filling pressures — the most specific physical sign of heart failure with reduced ejection fraction. A harsh systolic ejection murmur at the right upper sternal border radiating to the carotids is characteristic of aortic stenosis. A holosystolic murmur at the apex radiating to the axilla suggests mitral regurgitation. The combination of physical exam findings with symptom history determines the diagnostic hypothesis — and the hypothesis determines the test ordered next.
Step 2 — The 12-Lead ECG: The Essential Baseline
The 12-lead electrocardiogram (ECG) is performed in virtually every patient with suspected heart disease, providing immediate, inexpensive, and often diagnostically critical information about cardiac electrical activity:
What the ECG detects: Prior myocardial infarction leaves permanent ECG traces — pathological Q waves (duration greater than 40 ms, depth greater than 25% of the following R wave) in the leads corresponding to the infarcted territory. Anterior MI produces Q waves in V1 to V4 (LAD territory); inferior MI produces Q waves in leads II, III, and aVF (RCA territory); lateral MI produces Q waves in leads I, aVL, V5 to V6 (LCX territory). Acute ischemia produces dynamic ST-segment changes — ST elevation in the territory of the occluded artery (STEMI) or ST depression and T-wave inversion indicating subendocardial ischemia (NSTEMI or unstable angina). Left ventricular hypertrophy (LVH) is detected by voltage criteria (Sokolow-Lyon: S in V1 plus R in V5 or V6 greater than 35 mm) combined with a strain pattern (ST depression and T-wave inversion in lateral leads V5-V6) — indicating chronic pressure overload from hypertension or aortic stenosis.
Arrhythmia diagnosis: The ECG identifies atrial fibrillation (irregularly irregular rhythm with absent P waves), ventricular tachycardia (wide complex tachycardia with AV dissociation), supraventricular tachycardia (narrow complex regular tachycardia), heart block (prolonged PR interval in first-degree block; missing beats in second-degree block; complete AV dissociation in third-degree block), and accessory pathways (delta wave and short PR in Wolff-Parkinson-White syndrome — identifying pre-excitation that may cause life-threatening tachycardias). These rhythm diagnoses directly drive management: AF requires stroke risk assessment and anticoagulation; complete heart block requires pacemaker implantation; WPW with symptoms requires catheter ablation.
Step 3 — Blood Tests in Cardiac Diagnosis
Blood tests provide critical biochemical information that complements the clinical and electrical assessment in heart disease diagnosis:
Cardiac troponins: High-sensitivity cardiac troponin I (hs-cTnI) and troponin T (hs-cTnT) are the primary biomarkers for myocardial injury — released from cardiomyocytes when cell membrane integrity is disrupted by ischemia, inflammation, or other injury. In patients with suspected acute coronary syndrome, serial hs-troponin measurements at 0 and 1 to 3 hours (using the ESC 0h/1h or 0h/2h rapid rule-out algorithms) diagnose NSTEMI with sensitivity greater than 98% and NPV greater than 99% — enabling rapid safe discharge of low-risk patients or appropriate admission and further investigation for high-risk patients. Rising troponin (delta pattern) distinguishes acute myocardial infarction from stable elevation caused by non-ischemic myocardial injury (myocarditis, cardiac contusion, sepsis, pulmonary embolism, chronic kidney disease — all cause elevated troponin without the acute rising and falling pattern of MI).
BNP and NT-proBNP: Brain natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are secreted by ventricular cardiomyocytes in response to wall stress from elevated filling pressures. BNP and NT-proBNP confirm or exclude heart failure in patients with undifferentiated breathlessness: NT-proBNP below 125 pg/mL has a NPV of greater than 97% for excluding heart failure as the cause of dyspnea — making it an excellent rule-out test in primary care settings. Values above the age-stratified rule-in thresholds (greater than 450 pg/mL in patients under 50; greater than 900 pg/mL in patients 50 to 75; greater than 1800 pg/mL in patients over 75) confirm decompensated heart failure requiring immediate evaluation and treatment.
Lipid panel and metabolic markers: Fasting lipid panel (LDL-C, HDL-C, total cholesterol, triglycerides), HbA1c (glycated hemoglobin reflecting 3-month average blood glucose), fasting glucose, eGFR (kidney function — impaired renal function accelerates cardiovascular disease and modifies drug choices), and thyroid-stimulating hormone (TSH — hypothyroidism causes dyslipidemia and diastolic dysfunction; hyperthyroidism causes tachycardia and AF) are assessed as part of the cardiovascular risk factor evaluation in most patients referred for cardiac assessment. C-reactive protein (hsCRP — high-sensitivity) adds prognostic information about inflammatory cardiovascular risk beyond LDL-C, particularly in intermediate-risk patients being considered for statin therapy (Jupiter trial).
Step 4 — Non-Invasive Cardiac Imaging
After history, ECG, and blood tests establish the clinical picture, cardiac imaging provides structural and functional information to confirm the diagnosis, quantify disease severity, and guide treatment:
Transthoracic echocardiography (TTE): The single most informative non-invasive cardiac test — evaluating LV size and function (ejection fraction), regional wall motion (identifying prior MI territory by detecting regional hypokinesia or akinesia), valvular anatomy and function (detecting regurgitation or stenosis by Doppler velocity measurement), diastolic function (assessing LV filling pressure elevation), right heart size and pressure (estimated PASP from tricuspid regurgitation velocity), and pericardial effusion. TTE is indicated in virtually all patients with new cardiac diagnosis, unexplained symptoms, or monitoring of known cardiac disease.
Stress testing: When the pre-test CAD probability is intermediate and the clinical question is whether ischemia is present and how extensive, stress testing is the appropriate next step. The choice of stress modality depends on the patient’s ability to exercise (exercise preferred — provides additional prognostic information about functional capacity) and the ECG at baseline (LBBB, LVH with strain, or significant resting ST changes reduce exercise ECG interpretability — imaging stress tests preferred). Nuclear stress testing (myocardial perfusion imaging) has the highest sensitivity (85 to 90%); stress echocardiography has superior specificity and avoids radiation. Pharmacological stress (adenosine, regadenoson, or dobutamine) is used when patients cannot exercise.
See our related articles on common heart tests explained, angiogram: what patients should know, blood tests for heart health, coronary calcium score, and stress test for heart health. The American Heart Association cardiac diagnosis guide, NHLBI heart tests overview, and ACC/AHA chest pain guidelines 2021 provide authoritative clinical standards.
- Gulati M, et al. 2021 AHA/ACC/ASE Guideline for the Evaluation and Diagnosis of Chest Pain. J Am Coll Cardiol. 2021;78(22):e187-e285.
- Mueller C, et al. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes. JAMA. 2019;322(19):1878-1887.
- Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200.
- Knuuti J, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
- Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359(21):2195-2207.
Coronary CT Angiography — Ruling Out CAD Non-Invasively
Coronary computed tomography angiography (CTCA) has transformed the evaluation of patients with intermediate pre-test probability of coronary artery disease — providing non-invasive, high-resolution three-dimensional imaging of coronary artery anatomy with very high negative predictive value:
How CTCA works: Intravenous iodinated contrast is injected while the patient undergoes a fast CT scan synchronized to the ECG (prospective or retrospective ECG gating) to freeze cardiac motion during the diastolic phase when the heart is most still. The resulting 0.5–0.625 mm slice images are reconstructed into three-dimensional coronary artery maps allowing visualization of each coronary segment, quantification of luminal stenosis, and characterization of plaque composition (soft lipid-rich plaque versus calcified fibrous plaque versus mixed plaque). Modern scanners acquire a complete cardiac dataset in a single heartbeat (320-slice scanners, dual-source CT) — minimizing radiation exposure to 1 to 5 millisieverts for prospectively gated examinations (comparable to 6 to 18 months of background radiation).
Clinical role and evidence base: CTCA has a negative predictive value exceeding 99% for ruling out hemodynamically significant CAD (stenosis greater than 50%) — a normal CTCA effectively excludes significant coronary atherosclerosis in a patient with chest pain and intermediate pre-test probability. The PROMISE trial (10,003 patients, symptomatic chest pain, intermediate risk) demonstrated that a CTCA-guided strategy achieved equivalent rates of major adverse cardiac events compared to functional testing (nuclear or echo stress test) at 2-year follow-up, while identifying more obstructive CAD and leading to more appropriate preventive medical therapy. The SCOT-HEART trial demonstrated that CTCA-guided management reduced the 5-year rate of fatal and non-fatal MI compared to standard care — particularly by identifying non-obstructive CAD that prompted preventive statin initiation in patients who would otherwise have been reassured by a normal functional stress test. The 2021 ACC/AHA chest pain guidelines now recommend CTCA as a Class I indication for intermediate pre-test probability patients who can undergo testing (for appropriate vessels — non-calcified arteries; heavily calcified coronary arteries are better evaluated by invasive angiography).
Limitations: Calcium scoring (Agatston score from the non-contrast CT preceding CTCA) predicts CTCA image quality — high calcium burden (CACS above 400) causes blooming artifact that may overestimate stenosis severity, potentially requiring invasive angiography for definitive stenosis assessment. Patients with atrial fibrillation or heart rates above 70 to 75 bpm may have motion artifact that degrades image quality (though heart rate control with beta-blockade before the scan largely mitigates this). CTCA cannot perform functional stenosis assessment (FFR) — borderline stenoses detected on CTCA may require FFR-CT (computational fluid dynamics applied to CTCA images) or invasive FFR measurement to determine hemodynamic significance. Radiation and contrast exposure remain considerations for young patients requiring repeated surveillance.
Cardiac MRI — The Comprehensive Cardiac Tissue Characterization Tool
Cardiac magnetic resonance imaging (CMR) provides the most comprehensive non-invasive assessment of cardiac structure, function, and tissue composition available — without radiation. Its unique capability for tissue characterization (distinguishing fibrosis, edema, inflammation, and infiltration by their distinct MR signal properties) makes it irreplaceable for specific diagnostic questions that cannot be answered by other modalities:
Late gadolinium enhancement (LGE): The most diagnostically powerful CMR technique — gadolinium contrast distributes preferentially in areas of fibrosis (where normal cellular architecture is replaced by scar) and “enhances” (appears bright white) on T1-weighted imaging 10 to 15 minutes after injection. The pattern of LGE provides specific tissue diagnoses: subendocardial LGE in a coronary artery distribution (confined to the inner one-third to half of the myocardial wall, in the territory of a specific coronary artery) indicates prior myocardial infarction — the scar represents irreversibly infarcted myocardium that will not benefit from revascularization. Mid-wall or epicardial LGE — affecting the middle layers or outer layers of the myocardial wall rather than the subendocardium — indicates non-ischemic myocardial disease: myocarditis (active or prior), dilated cardiomyopathy, hypertrophic cardiomyopathy, sarcoidosis, arrhythmogenic cardiomyopathy, or cardiac amyloidosis (which produces global subendocardial LGE with distinctive dark blood pool pattern — classic for amyloid). The absence of LGE has equal diagnostic power — confirming the absence of irreversible myocardial injury in cases where echocardiography suggests possible wall motion abnormality.
Myocardial viability assessment: In patients with known coronary artery disease and reduced ejection fraction being considered for revascularization, CMR LGE quantifies the extent of transmural infarction in each segment — predicting which segments will recover function after revascularization. Segments with transmural infarction greater than 50% of wall thickness (bright LGE throughout more than 50% of the myocardial wall) are unlikely to recover function after revascularization and represent irreversible scar. Segments with LGE affecting less than 50% of wall thickness, or no LGE at all, with dysfunctional wall motion represent hibernating or stunned myocardium that can recover function after successful revascularization — the target of bypass surgery or PCI in ischemic cardiomyopathy patients.
Diagnosing Arrhythmias — The Electrophysiological Assessment
When structural heart disease evaluation is complete and the focus turns to rhythm disorders, the diagnostic evaluation of arrhythmias follows a separate pathway from coronary disease diagnosis:
Ambulatory ECG monitoring: For patients with episodic palpitations, syncope, or suspected arrhythmia where the resting ECG is normal — ambulatory monitoring extends the ECG recording window to capture the arrhythmia during symptoms. A 24-hour Holter monitor is appropriate for daily symptoms. A 14-day adhesive patch monitor (iRhythm Zio Patch — a single-lead continuous ECG recorder) provides significantly higher diagnostic yield for weekly or biweekly symptoms. A 30-day event monitor allows patient-triggered recording during infrequent symptomatic episodes. For very infrequent syncope (once every several months) or suspected paroxysmal AF in post-stroke patients, an implantable loop recorder — a subcutaneous device recording rhythm for up to 3 years — provides the highest diagnostic yield of any ambulatory monitoring strategy.
Electrophysiology study (EPS): When ambulatory monitoring is non-diagnostic and the clinical suspicion of a dangerous arrhythmia remains high — particularly in patients with structural heart disease, prior MI, reduced ejection fraction, or unexplained syncope — an invasive electrophysiology study is performed. Multiple catheters are advanced via the femoral veins to the right heart under fluoroscopic guidance, and programmed electrical stimulation protocols are used to provoke and characterize ventricular and supraventricular arrhythmias. Inducible sustained ventricular tachycardia in a patient with reduced ejection fraction (less than 35%) after prior MI is an indication for ICD implantation. Inducible SVT (AVNRT, AVRT, atrial flutter) may be ablated at the time of the EPS in the same procedure — catheter ablation for arrhythmias is now the preferred treatment for most SVTs and for symptomatic AF.
When Multiple Tests Are Needed — Understanding the Diagnostic Sequence
Patients undergoing cardiac evaluation sometimes find themselves referred for multiple tests in sequence and wonder why a simpler or more direct approach was not taken from the outset. The diagnostic sequence reflects a deliberate risk-stratification strategy that prioritizes non-invasive testing for ruling out disease or guiding management in the majority of patients — reserving more invasive and expensive testing for the minority who actually need it:
A patient with intermediate pre-test probability of CAD and typical angina follows this typical pathway: history and ECG (establish pre-test probability) → resting echo (evaluate LV function and valves) → CTCA or stress test (establish whether significant CAD is present) → if CTCA shows significant stenosis or stress test shows large ischemia → invasive coronary angiography with FFR (confirm anatomy and functional significance) → PCI or CABG if revascularization is indicated. Each step in this sequence adds information that justifies or redirects the next step — reflecting the Bayesian principle that prior probability of disease, updated by test results at each stage, determines what comes next. Jumping directly to invasive angiography in all patients referred for chest pain would expose low-risk patients to unnecessary procedural risk; working through non-invasive tests first identifies the minority who actually require angiography while providing reassurance and preventive therapy guidance for the majority.
Understanding this diagnostic logic — and knowing that a long diagnostic pathway does not necessarily indicate a serious diagnosis but rather a thorough evaluation — helps patients engage with the process with appropriate expectations and productive conversations with their cardiologist.